Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

Martin G. Klatt, MD, Zhiyuan Yang, PhD, Jianying Liu, PhD, Tatyana Korontsvit, MD, Sung Soo Mun, Leila Peraro, PhD, Thomas J. Gardner, PhD, Christopher Bourne, Megan M. Dacek, Tao Dao, MD PhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140179

Published: 2020

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

Martin G. Klatt, MD, Sung S. Mun, Nicholas D. Socci, PhD, Tatyana Korontsvit, MD, Tao Dao, MD PhD, David A. Scheinberg, MD PhD

Blood (2018) 132 (Supplement 1): 2717.

https://doi.org/10.1182/blood-2018-99-113691

Published: 2018

Journal Articles

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

Patrizia Mondello, MD MSc, Enrico Derenzini, MD, Zahra Asgari, John Philip, Elliot J Brea, PhD, Venkatraman E Seshan, PhD, Ronald Hendrickson, PhD, Elisa de Stanchina, PhD, David A Scheinberg, MD PhD, Anas Younes, MD

Blood (2016) 128 (22): 293.

https://doi.org/10.1182/blood.V128.22.293.293

Published: 2016

Journal Articles

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

Melissa D Mathias, MD, Jonathan T Sockolosky, PhD, Aaron Yu-Yuan Chang, BS, Cheng Liu, PhD, K. Christopher Garcia, PhD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4048.

https://doi.org/10.1182/blood.V128.22.4048.4048

Published: 2016

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Aaron Chang, Tao Dao, PhD, Andrew Scott, Leonid Dubrovsky, MD, Cheng Liu, PhD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 2527.

https://doi.org/10.1182/blood.V126.23.2527.2527

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2014) 124 (21): 5293.

https://doi.org/10.1182/blood.V124.21.5293.5293

Published: 2014

Journal Articles

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

Sarwish Rafiq, PhD, Tao Dao, MDPhD, Cheng Liu, PhD, David A. Scheinberg, MD PhD, Renier J Brentjens, MD PhD

Blood (2014) 124 (21): 2155.

https://doi.org/10.1182/blood.V124.21.2155.2155

Published: 2014

Journal Articles

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Dmitry Pankov, MD, Tao Dao, MD, PhD, Yiyang Wang, Andrew Scott, Tatyana Korontsvit, MD, Victoria Zakhaleva, Nicholas Veomett, Michael Curcio, Ekaterina Doubrovina, MD, PhD, Richard J. O'Reilly, MD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 2521.

https://doi.org/10.1182/blood.V122.21.2521.2521

Published: 2013

Journal Articles

Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors

Leonid Dubrovsky, MD, Elliott Brea, Dmitry Pankov, MD, Nicholas Veomett, Tao Dao, MD/PhD, Su Yan, PhD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 855.

https://doi.org/10.1182/blood.V122.21.855.855

Published: 2013

Journal Articles

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD, PhD, Jae H Park, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD, PhD

Blood (2013) 122 (21): 1460.

https://doi.org/10.1182/blood.V122.21.1460.1460

Published: 2013

Journal Articles

Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia.

Nicholas Veomett, Tao Dao, MD, PhD, Dmitry Pankov, MD, Su Yan, PhD, Richard J. O'Reilly, MD, Cheng Liu, PhD, David A. Scheinberg, MD, PhD

Blood (2012) 120 (21): 2599.

https://doi.org/10.1182/blood.V120.21.2599.2599

Published: 2012

Journal Articles

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Jeffrey R Gardner, MBA, Sean Devlin, PhD, Kristina Knapp, Francesco Bauli, MS, Nicole Lamanna, MD, Mark G. Frattini, MD, PhD, Renier J Brentjens, MD, PhD, Peter G. Maslak, M.D., Joseph G. Jurcic, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2012) 120 (21): 2482.

https://doi.org/10.1182/blood.V120.21.2482.2482

Published: 2012

Journal Articles

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Suzanne M. Chanel, RN, Tao Dao, MD, PhD, Yvette Bernal, Joseph G. Jurcic, MD, Rhong Zhang, Pamela Simancek, Martin S Tallman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 3624.

https://doi.org/10.1182/blood.V120.21.3624.3624

Published: 2012

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes

David A. Scheinberg, MD, PhD, Tao Dao, MD, PhD, Su Yan, PhD, Liang Zhou, PhD, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Cheng Liu, PhD

Blood (2011) 118 (21): 1677.

https://doi.org/10.1182/blood.V118.21.1677.1677

Published: 2011

Journal Articles

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Jeffrey R Gardner, MBA, Kristina Knapp, Mark G. Frattini, MD, PhD, Nicole Lamanna, MD, Renier Brentjens, MD, PhD, Joseph G Jurcic, MD, Peter G. Maslak, M.D., Ellin Berman, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2011) 118 (21): 1765.

https://doi.org/10.1182/blood.V118.21.1765.1765

Published: 2011

Journal Articles

Multi-Drug Resistance Phenotype in Myeloid Leukemia Cells Confers Radiation Resistance Via DNA Damage Sensor Uncoupling.

Jonathan H. Seideman, M.S., David A. Scheinberg, MD, PhD

Blood (2009) 114 (22): 4243.

https://doi.org/10.1182/blood.V114.22.4243.4243

Published: 2009

NARROW

A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells

Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Engineered T Cell Receptor-Mimic Antibody, (TCRm) Chimeric Antigen Receptor (CAR) T Cells Against the Intracellular Protein Wilms Tumor-1 (WT1) for Treatment of Hematologic and Solid Cancers

A Bi-Specific T Cell Engaging Monoclonal Antibody (mAb) Derived From a TCR-Like Mab Specific For WT1/HLA-A0201 (ESK-BiTE) Shows a Potent Activity Against Human AML and Ph+ ALL In Mouse Models

Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia.

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Multi-Drug Resistance Phenotype in Myeloid Leukemia Cells Confers Radiation Resistance Via DNA Damage Sensor Uncoupling.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only